Speakers 2021

Speakers 2021

John DE VOS

CHU Montpellier, INSERM U1183

Director of the Cell Processing Facility and of the Cord Blood Bank of the University Hospital of Montpellier


DRIVING iPS-DERIVED BRONCHIAL CELLS INTO THE CLINIC : MIND THE GAP

October 14th

We have recently developed a robust protocol to differentiate human iPS cells into bronchial epithelium, including ciliated cells, secretory cells or basal (stem) cells. Using CRISPR/Cas9 we were able to genetically repair an iPSC line obtained from a patient with primary ciliary dyskinesia (PCD) with a bi-allelic mutation of the CCDC40 gene. We postulate that it will be possible to treat PCD using autologous iPSC cells that have been repaired and differentiated into basal cell. To this aim, one last, but not least, obstacle is to identify an effective strategy to administrate the repaired cells. Hence, in lung diseases, as well as in many solid organs, the optimal way to inject cells is the last barrier to achieving regenerative medicine.

Find also